{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T10:00:04Z","timestamp":1773136804144,"version":"3.50.1"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Zhejiang Provincial Key Research and Development Program","award":["2021C03107"],"award-info":[{"award-number":["2021C03107"]}]},{"name":"the Leading Talent of Scientific and Technological Innovation - \"Ten Thousand Talents Program\" of Zhejiang Province","award":["2021R52016"],"award-info":[{"award-number":["2021R52016"]}]},{"name":"the Innovation team for precision diagnosis and treatment of major brain diseases","award":["2020R01001"],"award-info":[{"award-number":["2020R01001"]}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["226-2022-00193, 226-2022-00002"],"award-info":[{"award-number":["226-2022-00193, 226-2022-00002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-024-06141-z","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:02:17Z","timestamp":1729076537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of second-generation antipsychotics monotherapy or combined therapy in cytokine, lymphocyte subtype, and thyroid antibodies for schizophrenia: a retrospective study"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiaonan","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingzhuo","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizichen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"6141_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/scan\/nss012","volume":"8","author":"SJH Ebisch","year":"2013","unstructured":"Ebisch SJH, Salone A, Ferri F, De Berardis D, Romani GL, Ferro FM, et al. Out of touch with reality? Social perception in first-episode schizophrenia. Soc Cogn Affect Neurosci. 2013;8:394\u2013403.","journal-title":"Soc Cogn Affect Neurosci"},{"key":"6141_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","volume":"77","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-An Overview. JAMA Psychiatry. 2020;77:201\u201310.","journal-title":"JAMA Psychiatry"},{"key":"6141_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1073\/pnas.58.1.199","volume":"58","author":"II Gottesman","year":"1967","unstructured":"Gottesman II, Shields J. A polygenic theory of schizophrenia. Proc Natl Acad Sci U S A. 1967;58:199\u2013205.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6141_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/00325481.2021.2006514","volume":"134","author":"Z Ansari","year":"2022","unstructured":"Ansari Z, Pawar S, Seetharaman R. Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing? Postgrad Med. 2022;134:187\u201399.","journal-title":"Postgrad Med"},{"key":"6141_CR5","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/schbul\/sby024","volume":"44","author":"N M\u00fcller","year":"2018","unstructured":"M\u00fcller N. Inflammation in Schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr Bull. 2018;44:973\u201382.","journal-title":"Schizophr Bull"},{"key":"6141_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1037\/0021-843X.86.2.103","volume":"86","author":"J Zubin","year":"1977","unstructured":"Zubin J, Spring B. Vulnerability\u2013a new view of schizophrenia. J Abnorm Psychol. 1977;86:103\u201326.","journal-title":"J Abnorm Psychol"},{"key":"6141_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","volume":"2","author":"GM Khandaker","year":"2015","unstructured":"Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2:258\u201370.","journal-title":"Lancet Psychiatry"},{"key":"6141_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.bbi.2021.07.009","volume":"97","author":"BI Perry","year":"2021","unstructured":"Perry BI, Upthegrove R, Kappelmann N, Jones PB, Burgess S, Khandaker GM. Associations of immunological proteins\/traits with schizophrenia, major depression and bipolar disorder: a bi-directional two-sample mendelian randomization study. Brain Behav Immun. 2021;97:176\u201385.","journal-title":"Brain Behav Immun"},{"key":"6141_CR9","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.3390\/ijms25084291","volume":"25","author":"T Miyano","year":"2024","unstructured":"Miyano T, Mikkaichi T, Nakamura K, Yoshigae Y, Abernathy K, Ogura Y, et al. Circulating microRNA profiles identify a patient subgroup with high inflammation and severe symptoms in Schizophrenia experiencing Acute psychosis. Int J Mol Sci. 2024;25:4291.","journal-title":"Int J Mol Sci"},{"key":"6141_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12888-024-05621-6","volume":"24","author":"H Yang","year":"2024","unstructured":"Yang H, Peng R, Yang M, Zhang J, Shi Z, Zhang X. Association between elevated serum matrix metalloproteinase-2 and tumor necrosis factor-\u03b1, and clinical symptoms in male patients with treatment-resistant and chronic medicated schizophrenia. BMC Psychiatry. 2024;24:173.","journal-title":"BMC Psychiatry"},{"key":"6141_CR11","doi-asserted-by":"publisher","first-page":"1337103","DOI":"10.3389\/fimmu.2024.1337103","volume":"15","author":"C Yang","year":"2024","unstructured":"Yang C, Tian Y, Yang X, Liu L, Ling C, Xia L, et al. Hematological and inflammatory markers in Han Chinese patients with drug-free schizophrenia: relationship with symptom severity. Front Immunol. 2024;15:1337103.","journal-title":"Front Immunol"},{"key":"6141_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12974-022-02648-y","volume":"19","author":"HK Hughes","year":"2022","unstructured":"Hughes HK, Yang H, Lesh TA, Carter CS, Ashwood P. Evidence of innate immune dysfunction in first-episode psychosis patients with accompanying mood disorder. J Neuroinflammation. 2022;19:287.","journal-title":"J Neuroinflammation"},{"key":"6141_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2215-0366(23)00025-1","volume":"10","author":"S Halstead","year":"2023","unstructured":"Halstead S, Siskind D, Amft M, Wagner E, Yakimov V, Shih-Jung Liu Z, et al. Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry. 2023;10:260\u201371.","journal-title":"Lancet Psychiatry"},{"key":"6141_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.30773\/pi.2018.12.19.1","volume":"16","author":"N Trov\u00e3o","year":"2019","unstructured":"Trov\u00e3o N, Prata J, VonDoellinger O, Santos S, Barbosa M, Coelho R. Peripheral biomarkers for First-Episode Psychosis-opportunities from the Neuroinflammatory hypothesis of Schizophrenia. Psychiatry Investig. 2019;16:177\u201384.","journal-title":"Psychiatry Investig"},{"key":"6141_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajp.2017.01.026","volume":"26","author":"E Karanikas","year":"2017","unstructured":"Karanikas E, Manganaris S, Ntouros E, Floros G, Antoniadis D, Garyfallos G. Cytokines, cortisol and IGF-1 in first episode psychosis and ultra high risk males. Evidence for TNF-\u03b1, IFN-\u03b3, \u03a4NF-\u03b2, IL-4 deviation. Asian J Psychiatry. 2017;26:99\u2013103.","journal-title":"Asian J Psychiatry"},{"key":"6141_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.bbi.2023.03.014","volume":"110","author":"V Mondelli","year":"2023","unstructured":"Mondelli V, Blackman G, Kempton MJ, Pollak TA, Iyegbe C, Valmaggia LR, et al. Serum immune markers and transition to psychosis in individuals at clinical high risk. Brain Behav Immun. 2023;110:290\u20136.","journal-title":"Brain Behav Immun"},{"key":"6141_CR17","doi-asserted-by":"publisher","first-page":"105200","DOI":"10.1016\/j.psyneuen.2021.105200","volume":"127","author":"B Misiak","year":"2021","unstructured":"Misiak B, Bartoli F, Carr\u00e0 G, Sta\u0144czykiewicz B, G\u0142adka A, Frydecka D, et al. Immune-inflammatory markers and psychosis risk: a systematic review and meta-analysis. Psychoneuroendocrinology. 2021;127:105200.","journal-title":"Psychoneuroendocrinology"},{"key":"6141_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/acps.13416","volume":"146","author":"C Dunleavy","year":"2022","unstructured":"Dunleavy C, Elsworthy RJ, Upthegrove R, Wood SJ, Aldred S. Inflammation in first-episode psychosis: the contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis. Acta Psychiatr Scand. 2022;146:6\u201320.","journal-title":"Acta Psychiatr Scand"},{"key":"6141_CR19","doi-asserted-by":"publisher","first-page":"110668","DOI":"10.1016\/j.pnpbp.2022.110668","volume":"121","author":"SR Patlola","year":"2023","unstructured":"Patlola SR, Donohoe G, McKernan DP. The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2023;121:110668.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"6141_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics Consortium","year":"2014","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421\u20137.","journal-title":"Nature"},{"key":"6141_CR21","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","volume":"52","author":"V Orr\u00f9","year":"2020","unstructured":"Orr\u00f9 V, Steri M, Sidore C, Marongiu M, Serra V, Olla S, et al. Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat Genet. 2020;52:1036\u201345.","journal-title":"Nat Genet"},{"key":"6141_CR22","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1186\/s12888-023-05081-4","volume":"23","author":"C Wang","year":"2023","unstructured":"Wang C, Zhu D, Zhang D, Zuo X, Yao L, Liu T, et al. Causal role of immune cells in schizophrenia: mendelian randomization (MR) study. BMC Psychiatry. 2023;23:590.","journal-title":"BMC Psychiatry"},{"key":"6141_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.biopsych.2012.09.007","volume":"73","author":"BJ Miller","year":"2013","unstructured":"Miller BJ, Gassama B, Sebastian D, Buckley P, Mellor A. Meta-analysis of lymphocytes in Schizophrenia: clinical Status and Antipsychotic effects. Biol Psychiatry. 2013;73:993\u20139.","journal-title":"Biol Psychiatry"},{"key":"6141_CR24","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature07201","volume":"454","author":"R Medzhitov","year":"2008","unstructured":"Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428\u201335.","journal-title":"Nature"},{"key":"6141_CR25","first-page":"1801","volume":"50","author":"J Doorduin","year":"2009","unstructured":"Doorduin J, de Vries EFJ, Willemsen ATM, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med off Publ Soc Nucl Med. 2009;50:1801\u20137.","journal-title":"J Nucl Med off Publ Soc Nucl Med"},{"key":"6141_CR26","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.biopsych.2008.04.025","volume":"64","author":"BN van Berckel","year":"2008","unstructured":"van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11\u00a0C]PK11195 positron emission tomography study. Biol Psychiatry. 2008;64:820\u20132.","journal-title":"Biol Psychiatry"},{"key":"6141_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1741-7015-4-29","volume":"4","author":"DE Job","year":"2006","unstructured":"Job DE, Whalley HC, McIntosh AM, Owens DGC, Johnstone EC, Lawrie SM. Grey matter changes can improve the prediction of schizophrenia in subjects at high risk. BMC Med. 2006;4:29.","journal-title":"BMC Med"},{"key":"6141_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1192\/bjp.186.1.26","volume":"186","author":"MH Chakos","year":"2005","unstructured":"Chakos MH, Schobel SA, Gu H, Gerig G, Bradford D, Charles C, et al. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br J Psychiatry J Ment Sci. 2005;186:26\u201331.","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"6141_CR29","doi-asserted-by":"publisher","first-page":"15979","DOI":"10.1073\/pnas.0806485105","volume":"105","author":"N Gogtay","year":"2008","unstructured":"Gogtay N, Lu A, Leow AD, Klunder AD, Lee AD, Chavez A, et al. Three-dimensional brain growth abnormalities in childhood-onset schizophrenia visualized by using tensor-based morphometry. Proc Natl Acad Sci U S A. 2008;105:15979\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6141_CR30","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1192\/bjp.188.6.510","volume":"188","author":"RG Steen","year":"2006","unstructured":"Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry J Ment Sci. 2006;188:510\u20138.","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"6141_CR31","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1176\/appi.ajp.158.8.1316","volume":"158","author":"EM Meisenzahl","year":"2001","unstructured":"Meisenzahl EM, Rujescu D, Kirner A, Giegling I, Kathmann N, Leinsinger G, et al. Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. Am J Psychiatry. 2001;158:1316\u20139.","journal-title":"Am J Psychiatry"},{"key":"6141_CR32","doi-asserted-by":"publisher","first-page":"110510","DOI":"10.1016\/j.pnpbp.2022.110510","volume":"116","author":"A Michalczyk","year":"2022","unstructured":"Michalczyk A, Tyburski E, Podwalski P, Waszczuk K, Rudkowski K, Kucharska-Mazur J, et al. Serum inflammatory markers and their associations with white matter integrity of the corpus callosum in schizophrenia patients and healthy controls. Prog Neuropsychopharmacol Biol Psychiatry. 2022;116:110510.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"6141_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/schbul\/sbad114","volume":"50","author":"M Gou","year":"2024","unstructured":"Gou M, Chen W, Li Y, Chen S, Feng W, Pan S, et al. Immune-Inflammatory Response and Compensatory Immune-Regulatory Reflex systems and White Matter Integrity in Schizophrenia. Schizophr Bull. 2024;50:199\u2013209.","journal-title":"Schizophr Bull"},{"key":"6141_CR34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12916-023-02963-y","volume":"21","author":"L-B Cui","year":"2023","unstructured":"Cui L-B, Wang X-Y, Fu Y-F, Liu X-F, Wei Y, Zhao S-W, et al. Transcriptional level of inflammation markers associates with short-term brain structural changes in first-episode schizophrenia. BMC Med. 2023;21:250.","journal-title":"BMC Med"},{"key":"6141_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.bbi.2023.06.023","volume":"113","author":"P Alexandros Lalousis","year":"2023","unstructured":"Alexandros Lalousis P, Schmaal L, Wood SJ, L E P Reniers R, Cropley VL, Watson A, et al. Inflammatory subgroups of schizophrenia and their association with brain structure: a semi-supervised machine learning examination of heterogeneity. Brain Behav Immun. 2023;113:166\u201375.","journal-title":"Brain Behav Immun"},{"key":"6141_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.biopsych.2022.11.003","volume":"93","author":"DR Goldsmith","year":"2023","unstructured":"Goldsmith DR, Bekhbat M, Mehta ND, Felger JC. Inflammation-related functional and Structural Dysconnectivity as a pathway to psychopathology. Biol Psychiatry. 2023;93:405\u201318.","journal-title":"Biol Psychiatry"},{"key":"6141_CR37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jad.2022.09.044","volume":"319","author":"DJ Bond","year":"2022","unstructured":"Bond DJ, Andreazza AC, Torres IJ, Honer WG, Lam RW, Yatham LN. Association of total peripheral inflammation with lower frontal and temporal lobe volumes in early-stage bipolar disorder: a proof-of-concept study. J Affect Disord. 2022;319:229\u201334.","journal-title":"J Affect Disord"},{"key":"6141_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1749-6632.1998.tb09556.x","volume":"840","author":"A Kabiersch","year":"1998","unstructured":"Kabiersch A, Furukawa H, del Rey A, Besedovsky HO. Administration of interleukin-1 at birth affects dopaminergic neurons in adult mice. Ann N Y Acad Sci. 1998;840:123\u20137.","journal-title":"Ann N Y Acad Sci"},{"key":"6141_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bbi.2016.07.144","volume":"63","author":"C Meehan","year":"2017","unstructured":"Meehan C, Harms L, Frost JD, Barreto R, Todd J, Schall U, et al. Effects of immune activation during early or late gestation on schizophrenia-related behaviour in adult rat offspring. Brain Behav Immun. 2017;63:8\u201320.","journal-title":"Brain Behav Immun"},{"key":"6141_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-024-03987-y","author":"JA Cale","year":"2024","unstructured":"Cale JA, Chauhan EJ, Cleaver JJ, Fusciardi AR, McCann S, Waters HC, et al. GABAergic and inflammatory changes in the frontal cortex following neonatal PCP plus isolation rearing, as a dual-hit neurodevelopmental model for schizophrenia. Mol Neurobiol. 2024. https:\/\/doi.org\/10.1007\/s12035-024-03987-y.","journal-title":"Mol Neurobiol"},{"key":"6141_CR41","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.bbi.2023.05.001","volume":"111","author":"P Le\u00f3n-Ortiz","year":"2023","unstructured":"Le\u00f3n-Ortiz P, Rivera-Ch\u00e1vez LF, Torres-Ru\u00edz J, Reyes-Madrigal F, Carrillo-V\u00e1zquez D, Moncada-Habib T, et al. Systemic inflammation and cortical neurochemistry in never-medicated first episode-psychosis individuals. Brain Behav Immun. 2023;111:270\u20136.","journal-title":"Brain Behav Immun"},{"key":"6141_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1176\/appi.ajp.163.3.521","volume":"163","author":"WW Eaton","year":"2006","unstructured":"Eaton WW, Byrne M, Ewald H, Mors O, Chen C-Y, Agerbo E, et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry. 2006;163:521\u20138.","journal-title":"Am J Psychiatry"},{"key":"6141_CR43","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/schbul\/17.4.669","volume":"17","author":"S Vinogradov","year":"1991","unstructured":"Vinogradov S, Gottesman II, Moises HW, Nicol S. Negative Association between Schizophrenia and Rheumatoid Arthritis. Schizophr Bull. 1991;17:669\u201378.","journal-title":"Schizophr Bull"},{"key":"6141_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0165-1781(91)90051-P","volume":"38","author":"LE DeLisi","year":"1991","unstructured":"DeLisi LE, Boccio AM, Riordan H, Hoff AL, Dorfman A, McClelland J, et al. Familial thyroid disease and delayed language development in first admission patients with schizophrenia. Psychiatry Res. 1991;38:39\u201350.","journal-title":"Psychiatry Res"},{"key":"6141_CR45","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/BF01566581","volume":"35","author":"H Graff","year":"1961","unstructured":"Graff H, Handford A. Celiac syndrome in the case histories of five schizophrenics. Psychiatr Q. 1961;35:306\u201313.","journal-title":"Psychiatr Q"},{"key":"6141_CR46","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1176\/appi.ajp.2013.13010086","volume":"171","author":"ME Benros","year":"2014","unstructured":"Benros ME, Pedersen MG, Rasmussen H, Eaton WW, Nordentoft M, Mortensen PB. A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. Am J Psychiatry. 2014;171:218\u201326.","journal-title":"Am J Psychiatry"},{"key":"6141_CR47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1749-6632.2012.06638.x","volume":"1262","author":"ME Benros","year":"2012","unstructured":"Benros ME, Mortensen PB, Eaton WW. Autoimmune diseases and infections as risk factors for schizophrenia. Ann N Y Acad Sci. 2012;1262:56\u201366.","journal-title":"Ann N Y Acad Sci"},{"key":"6141_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-020-00967-3","volume":"10","author":"D Endres","year":"2020","unstructured":"Endres D, Meixensberger S, Dersch R, Feige B, Stich O, Venhoff N, et al. Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis. Transl Psychiatry. 2020;10:1\u201320.","journal-title":"Transl Psychiatry"},{"key":"6141_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0920-9964(94)90004-3","volume":"14","author":"AE Henneberg","year":"1994","unstructured":"Henneberg AE, Horter S, Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr Res. 1994;14:15\u201322.","journal-title":"Schizophr Res"},{"key":"6141_CR50","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/0006-3223(91)90217-A","volume":"29","author":"S Shima","year":"1991","unstructured":"Shima S, Yano K, Sugiura M, Tokunaga Y. Anticerebral antibodies in functional psychoses. Biol Psychiatry. 1991;29:322\u20138.","journal-title":"Biol Psychiatry"},{"key":"6141_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-024-02853-8","volume":"14","author":"E Darrau","year":"2024","unstructured":"Darrau E, Jacquemet E, Pons S, Schlick L, Zouridakis M, Wu C-L, et al. Serum autoantibodies against \u03b17-nicotinic receptors in subgroups of patients with bipolar disorder or schizophrenia: clinical features and link with peripheral inflammation. Transl Psychiatry. 2024;14:1\u201313.","journal-title":"Transl Psychiatry"},{"key":"6141_CR52","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00213-013-3383-3","volume":"231","author":"V Mondelli","year":"2014","unstructured":"Mondelli V, Howes O. Inflammation: its role in schizophrenia and the potential anti-inflammatory effects of antipsychotics. Psychopharmacology. 2014;231:317\u20138.","journal-title":"Psychopharmacology"},{"key":"6141_CR53","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","volume":"70","author":"BJ Miller","year":"2011","unstructured":"Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663\u201371.","journal-title":"Biol Psychiatry"},{"key":"6141_CR54","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2174\/1570159X22666231128101725","volume":"22","author":"A Amerio","year":"2024","unstructured":"Amerio A, Magnani L, Arduino G, Fesce F, de Filippis R, Parise A, et al. Immunomodulatory effects of Clozapine: more than just a side effect in Schizophrenia. Curr Neuropharmacol. 2024;22:1233\u201347.","journal-title":"Curr Neuropharmacol"},{"key":"6141_CR55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41398-023-02507-1","volume":"13","author":"JD Villar","year":"2023","unstructured":"Villar JD, Stavrum A-K, Spindola LM, Torsvik A, Bjella T, Steen NE, et al. Differences in white blood cell proportions between schizophrenia cases and controls are influenced by medication and variations in time of day. Transl Psychiatry. 2023;13:211.","journal-title":"Transl Psychiatry"},{"key":"6141_CR56","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.pharep.2014.09.007","volume":"67","author":"J Sobi\u015b","year":"2015","unstructured":"Sobi\u015b J, Rykaczewska-Czerwi\u0144ska M, \u015awi\u0119tochowska E, Gorczyca P. Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity. Pharmacol Rep PR. 2015;67:353\u20139.","journal-title":"Pharmacol Rep PR"},{"key":"6141_CR57","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jpsychires.2023.01.042","volume":"160","author":"SR Patlola","year":"2023","unstructured":"Patlola SR, Donohoe G, McKernan DP. Anti-inflammatory effects of 2nd generation antipsychotics in patients with schizophrenia: a systematic review and meta-analysis. J Psychiatr Res. 2023;160:126\u201336.","journal-title":"J Psychiatr Res"},{"key":"6141_CR58","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bbi.2019.02.021","volume":"79","author":"L Wang","year":"2019","unstructured":"Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: a systematic review and meta-analysis. Brain Behav Immun. 2019;79:24\u201338.","journal-title":"Brain Behav Immun"},{"key":"6141_CR59","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3390\/ijms22041532","volume":"22","author":"K Sakrajda","year":"2021","unstructured":"Sakrajda K, Szczepankiewicz A. Inflammation-related changes in Mood disorders and the Immunomodulatory Role of Lithium. Int J Mol Sci. 2021;22:1532.","journal-title":"Int J Mol Sci"},{"key":"6141_CR60","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1006\/phrs.2001.0800","volume":"43","author":"P Fruscella","year":"2001","unstructured":"Fruscella P, Sottocorno M, Di Braccio M, Diomede L, Piccardi N, Cagnotto A, et al. 1,5-Benzodiazepine tricyclic derivatives exerting anti-inflammatory effects in mice by inhibiting interleukin-6 and prostaglandinE(2)production. Pharmacol Res. 2001;43:445\u201352.","journal-title":"Pharmacol Res"},{"key":"6141_CR61","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1176\/ajp.142.11.1355","volume":"142","author":"AM Gruenberg","year":"1985","unstructured":"Gruenberg AM, Kendler KS, Tsuang MT. Reliability and concordance in the subtyping of schizophrenia. Am J Psychiatry. 1985;142:1355\u20138.","journal-title":"Am J Psychiatry"},{"key":"6141_CR62","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","volume":"400","author":"JH Krystal","year":"2022","unstructured":"Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet Lond Engl. 2022;400:2210\u201320.","journal-title":"Lancet Lond Engl"},{"key":"6141_CR63","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet Lond Engl. 2024;403:160\u201370.","journal-title":"Lancet Lond Engl"},{"key":"6141_CR64","doi-asserted-by":"publisher","first-page":"e14361","DOI":"10.1111\/cns.14361","volume":"30","author":"S Li","year":"2023","unstructured":"Li S, Lv D, Qian C, Jiang J, Zhang P, Xi C, et al. Circulating T-cell subsets discrepancy between bipolar disorder and major depressive disorder during mood episodes: a naturalistic, retrospective study of 1015 cases. CNS Neurosci Ther. 2023;30:e14361.","journal-title":"CNS Neurosci Ther"},{"key":"6141_CR65","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/schbul\/sbv028","volume":"41","author":"V Mondelli","year":"2015","unstructured":"Mondelli V, Ciufolini S, Belvederi Murri M, Bonaccorso S, Di Forti M, Giordano A, et al. Cortisol and inflammatory biomarkers predict poor treatment response in First Episode Psychosis. Schizophr Bull. 2015;41:1162\u201370.","journal-title":"Schizophr Bull"},{"key":"6141_CR66","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.neubiorev.2017.03.003","volume":"77","author":"E Capuzzi","year":"2017","unstructured":"Capuzzi E, Bartoli F, Crocamo C, Clerici M, Carr\u00e0 G. Acute variations of cytokine levels after antipsychotic treatment in drug-na\u00efve subjects with a first-episode psychosis: a meta-analysis. Neurosci Biobehav Rev. 2017;77:122\u20138.","journal-title":"Neurosci Biobehav Rev"},{"key":"6141_CR67","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.schres.2019.03.012","volume":"226","author":"S Park","year":"2020","unstructured":"Park S, Miller BJ. Meta-analysis of cytokine and C-reactive protein levels in high-risk psychosis. Schizophr Res. 2020;226:5\u201312.","journal-title":"Schizophr Res"},{"key":"6141_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-024-01786-z","author":"F Facal","year":"2024","unstructured":"Facal F, Arrojo M, P\u00e1ramo M, Costas J. Association between psychiatric admissions in patients with schizophrenia and IL-6 plasma levels polygenic score. Eur Arch Psychiatry Clin Neurosci. 2024. https:\/\/doi.org\/10.1007\/s00406-024-01786-z.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"6141_CR69","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/schbul\/sbt139","volume":"40","author":"IE Sommer","year":"2014","unstructured":"Sommer IE, van Westrhenen R, Begemann MJH, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with Schizophrenia: an update. Schizophr Bull. 2014;40:181\u201391.","journal-title":"Schizophr Bull"},{"key":"6141_CR70","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbi.2023.08.001","volume":"114","author":"A Chandra","year":"2023","unstructured":"Chandra A, Miller BJ, Goldsmith DR. Predictors of successful anti-inflammatory drug trials in patients with schizophrenia: a meta-regression and critical commentary. Brain Behav Immun. 2023;114:154\u201362.","journal-title":"Brain Behav Immun"},{"key":"6141_CR71","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/s41386-023-01760-8","volume":"49","author":"D-M Wang","year":"2024","unstructured":"Wang D-M, Chen D-C, Xiu M-H, Wang L, Kosten TR, Zhang X-Y. A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-na\u00efve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms. Neuropsychopharmacol off Publ Am Coll Neuropsychopharmacol. 2024;49:893\u2013902.","journal-title":"Neuropsychopharmacol off Publ Am Coll Neuropsychopharmacol"},{"key":"6141_CR72","doi-asserted-by":"publisher","first-page":"3476240","DOI":"10.1155\/2016\/3476240","volume":"2016","author":"S Marini","year":"2016","unstructured":"Marini S, De Berardis D, Vellante F, Santacroce R, Orsolini L, Valchera A, et al. Celecoxib Adjunctive Treatment to antipsychotics in Schizophrenia: a review of Randomized Clinical Add-On trials. Mediators Inflamm. 2016;2016:3476240.","journal-title":"Mediators Inflamm"},{"key":"6141_CR73","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bbi.2023.10.012","volume":"115","author":"TW Weickert","year":"2024","unstructured":"Weickert TW, Jacomb I, Lenroot R, Lappin J, Weinberg D, Brooks WS, et al. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: a randomized control trial. Brain Behav Immun. 2024;115:191\u2013200.","journal-title":"Brain Behav Immun"},{"key":"6141_CR74","doi-asserted-by":"publisher","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","volume":"71","author":"W Laan","year":"2010","unstructured":"Laan W, Grobbee DE, Selten J-P, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71:520\u20137.","journal-title":"J Clin Psychiatry"},{"key":"6141_CR75","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/archgenpsychiatry.2009.192","volume":"67","author":"GP Amminger","year":"2010","unstructured":"Amminger GP, Sch\u00e4fer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67:146\u201354.","journal-title":"Arch Gen Psychiatry"},{"key":"6141_CR76","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41398-023-02570-8","volume":"13","author":"SE Herniman","year":"2023","unstructured":"Herniman SE, Wood SJ, Khandaker G, Dazzan P, Pariante CM, Barnes NM, et al. Network analysis of inflammation and symptoms in recent onset schizophrenia and the influence of minocycline during a clinical trial. Transl Psychiatry. 2023;13:297.","journal-title":"Transl Psychiatry"},{"key":"6141_CR77","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.schres.2011.08.005","volume":"133","author":"DL Kelly","year":"2011","unstructured":"Kelly DL, Vyas G, Richardson CM, Koola M, McMahon RP, Buchanan RW, et al. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res. 2011;133:257\u20138.","journal-title":"Schizophr Res"},{"key":"6141_CR78","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.4088\/JCP.09m05031yel","volume":"71","author":"MS Ritsner","year":"2010","unstructured":"Ritsner MS, Gibel A, Shleifer T, Boguslavsky I, Zayed A, Maayan R, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry. 2010;71:1351\u201362.","journal-title":"J Clin Psychiatry"},{"key":"6141_CR79","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","volume":"64","author":"M Berk","year":"2008","unstructured":"Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia\u2013a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64:361\u20138.","journal-title":"Biol Psychiatry"},{"key":"6141_CR80","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/S1567-5769(02)00190-X","volume":"2","author":"A Nishida","year":"2002","unstructured":"Nishida A, Hisaoka K, Zensho H, Uchitomi Y, Morinobu S, Yamawaki S. Antidepressant drugs and cytokines in mood disorders. Int Immunopharmacol. 2002;2:1619\u201326.","journal-title":"Int Immunopharmacol"},{"key":"6141_CR81","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0163-7258(97)00055-7","volume":"75","author":"F Zavala","year":"1997","unstructured":"Zavala F. Benzodiazepines, anxiety and immunity. Pharmacol Ther. 1997;75:199\u2013216.","journal-title":"Pharmacol Ther"},{"key":"6141_CR82","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.jpsychires.2013.07.026","volume":"47","author":"H Himmerich","year":"2013","unstructured":"Himmerich H, Bartsch S, Hamer H, Mergl R, Sch\u00f6nherr J, Petersein C, et al. Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro. J Psychiatr Res. 2013;47:1751\u20139.","journal-title":"J Psychiatr Res"},{"key":"6141_CR83","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jad.2016.06.016","volume":"203","author":"S van den Ameele","year":"2016","unstructured":"van den Ameele S, van Diermen L, Staels W, Coppens V, Dumont G, Sabbe B, et al. The effect of mood-stabilizing drugs on cytokine levels in bipolar disorder: a systematic review. J Affect Disord. 2016;203:364\u201373.","journal-title":"J Affect Disord"},{"key":"6141_CR84","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.bbi.2020.10.026","volume":"91","author":"CR Krynicki","year":"2021","unstructured":"Krynicki CR, Dazzan P, Pariante CM, Barnes NM, Vincent RC, Roberts A, et al. Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment. Brain Behav Immun. 2021;91:498\u2013504.","journal-title":"Brain Behav Immun"},{"key":"6141_CR85","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bbi.2016.02.005","volume":"54","author":"P Karpi\u0144ski","year":"2016","unstructured":"Karpi\u0144ski P, Frydecka D, S\u0105siadek MM, Misiak B. Reduced number of peripheral natural killer cells in schizophrenia but not in bipolar disorder. Brain Behav Immun. 2016;54:194\u2013200.","journal-title":"Brain Behav Immun"},{"key":"6141_CR86","doi-asserted-by":"publisher","first-page":"646287","DOI":"10.3389\/fphar.2021.646287","volume":"12","author":"M Rasool","year":"2021","unstructured":"Rasool M, Malik A, Saleem S, Ashraf MAB, Khan AQ, Waquar S, et al. Role of oxidative stress and the identification of biomarkers Associated with thyroid dysfunction in Schizophrenics. Front Pharmacol. 2021;12:646287.","journal-title":"Front Pharmacol"},{"key":"6141_CR87","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3109\/07853899309147317","volume":"25","author":"R Ganguli","year":"1993","unstructured":"Ganguli R, Brar JS, Chengappa KN, Yang ZW, Nimgaonkar VL, Rabin BS. Autoimmunity in schizophrenia: a review of recent findings. Ann Med. 1993;25:489\u201396.","journal-title":"Ann Med"},{"key":"6141_CR88","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.neubiorev.2021.03.004","volume":"125","author":"F Corsi-Zuelli","year":"2021","unstructured":"Corsi-Zuelli F, Deakin B. Impaired regulatory T cell control of astroglial overdrive and microglial pruning in schizophrenia. Neurosci Biobehav Rev. 2021;125:637\u201353.","journal-title":"Neurosci Biobehav Rev"},{"key":"6141_CR89","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/0024-3205(95)02047-M","volume":"57","author":"LR Watkins","year":"1995","unstructured":"Watkins LR, Maier SF, Goehler LE. Cytokine-to-brain communication: a review & analysis of alternative mechanisms. Life Sci. 1995;57:1011\u201326.","journal-title":"Life Sci"},{"key":"6141_CR90","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2174\/1381612053381684","volume":"11","author":"WA Banks","year":"2005","unstructured":"Banks WA. Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des. 2005;11:973\u201384.","journal-title":"Curr Pharm Des"},{"key":"6141_CR91","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1176\/appi.ajp.157.5.683","volume":"157","author":"Z Kronfol","year":"2000","unstructured":"Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157:683\u201394.","journal-title":"Am J Psychiatry"},{"key":"6141_CR92","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1176\/appi.ajp.2009.09030361","volume":"167","author":"AS Brown","year":"2010","unstructured":"Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 2010;167:261\u201380.","journal-title":"Am J Psychiatry"},{"key":"6141_CR93","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1017\/S0033291712000736","volume":"43","author":"GM Khandaker","year":"2013","unstructured":"Khandaker GM, Zimbron J, Lewis G, Jones PB. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med. 2013;43:239\u201357.","journal-title":"Psychol Med"},{"key":"6141_CR94","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.schres.2012.05.023","volume":"139","author":"GM Khandaker","year":"2012","unstructured":"Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB. Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr Res. 2012;139:161\u20138.","journal-title":"Schizophr Res"},{"key":"6141_CR95","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1176\/appi.ajp.2011.11030516","volume":"168","author":"ME Benros","year":"2011","unstructured":"Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry. 2011;168:1303\u201310.","journal-title":"Am J Psychiatry"},{"key":"6141_CR96","doi-asserted-by":"publisher","first-page":"110866","DOI":"10.1016\/j.pnpbp.2023.110866","volume":"128","author":"DH Adamowicz","year":"2024","unstructured":"Adamowicz DH, Wu T-C, Daly R, Irwin MR, Jeste DV, Tu XM, et al. Executive functioning trajectories and their prospective association with inflammatory biomarkers in schizophrenia and non-psychiatric comparison participants. Prog Neuropsychopharmacol Biol Psychiatry. 2024;128:110866.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"6141_CR97","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41380-022-01924-w","volume":"28","author":"LS S\u00e6ther","year":"2023","unstructured":"S\u00e6ther LS, Ueland T, Haatveit B, Maglanoc LA, Szabo A, Djurovic S, et al. Inflammation and cognition in severe mental illness: patterns of covariation and subgroups. Mol Psychiatry. 2023;28:1284\u201392.","journal-title":"Mol Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06141-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-06141-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06141-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T23:03:49Z","timestamp":1729119829000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-06141-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6141"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-06141-z","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"4 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (ITT20240569A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The funders had no role in the study design; collection, analysis, and interpretation of data; writing of the report; and decision to submit the article for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the funding source"}},{"value":"Due to the retrospective, non-interventional, and anonymous nature of this study, written informed consent from patients was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"No animals were used for studies that are the basis of this research. All human procedures followed were in accordance with the Helsinki Declaration of 1975.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Not applicable since this is a retrospective study rather a clinical trial.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"The authors declare no competing interests.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"695"}}